Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hypertonic Saline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2016
Lead Product(s) : Hypertonic Saline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 13, 2016
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 07, 2016
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idrevloride
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2016
Lead Product(s) : Idrevloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-1037
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2015
Lead Product(s) : P-1037
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Vertex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 16, 2014
Lead Product(s) : P-321
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : P-552
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 09, 2011
Lead Product(s) : P-552
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
